Rapid construction method of plateau encephaledema animal model

Through intraperitoneal injection of desmopressin acetate and simulated low-pressure environment exposure of 4500 meters above sea level for 24 hours, the problem of the inability to quickly establish an animal model of plateau brain edema in the existing technology is solved, and a rapid and efficient model construction is achieved, and it is in line with humans. Pathological characteristics of plateau cerebral edema.

CN119014369APending Publication Date: 2024-11-26青海省人民医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411406661.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art cannot induce plateau cerebral edema in animals within 1 day in a simulated environment below 5,000 meters above sea level, and cannot quickly establish a plateau cerebral edema animal model that conforms to the characteristics of human diseases.

Method used

By injecting desmopressin acetate intraperitoneal cavity and exposed to low-pressure environments with a simulated altitude of 4,500 meters for 24 hours, combined with real-time monitoring of oxygen and carbon dioxide concentrations, an animal model of plateau brain edema was quickly constructed.

Benefits of technology

The rapid establishment of an animal model of plateau brain edema within 1 day was achieved, which shortened the model construction time and improved the model construction efficiency. The model's hippocampus neuron degeneration necrosis rate and brain water content increased in line with the pathological characteristics of human plateau brain edema.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119014369A_ABST
    Figure CN119014369A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of animal model construction, in particular to a rapid construction method of a plateau encephaledema animal model. The method comprises the following steps: 1, injecting desmopressin acetate into the abdominal cavity of an experimental animal; 2, working parameters of the experiment module are set, the simulation altitude is set to be 4500 m, the modeling time is 24 hours, and the temperature during modeling is 24-26 DEG C; 3, the experimental animals in the step 1 are placed in an experimental cabin, and drinking water is put into the experimental cabin for free taking and using; 4, starting the experiment module, and continuously modeling the experimental animal for 24 hours in a low-pressure environment in the experiment module; step 5, during the working period of the experiment module, monitoring the concentration of oxygen and carbon dioxide in the module in real time, maintaining the oxygen partial pressure to be 11.6 kPa to 12.2 kPa, and maintaining the volume ratio of carbon dioxide to be not more than 0.5%; and step 6, finishing modeling, recovering the normal pressure of the experiment cabin, opening the cabin door, taking out the experimental animal, and finishing modeling. The constructed animal model can well simulate pathological characteristics and symptoms of plateau encephaledema, and the construction method is simple and convenient and has good repeatability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of animal model construction, and in particular to a method for rapidly constructing an animal model of high altitude cerebral edema. Background Art

[0002] Areas above 2,500 meters above sea level can produce significant biological effects, and these areas are defined as "plateaus". Various pathological reactions caused by the human body entering the plateau are called altitude sickness, among which acute mountain sickness that occurs within 1 week of entering the plateau is called acute mountain sickness. High-altitude cerebral edema is a serious and fatal terminal manifestation of acute mountain sickness. The overall incidence of high-altitude cerebral edema in people entering the plateau is 0.5% to 1.5%. About 26% of my country's land area is plateau. The occurrence of altitude sickness has a negative impact on the health of many people who go to or live in the plateau, and even endangers their lives. Continuous in-depth research on the causes and mechanisms of high-altitude diseases, including high-altitude cerebral edema, and the development of new prevention and treatment methods are of great significance to ensuring the economic development of the plateau and maintaining ecological and national defense security. Disease animal models provide an important basis for in-depth exploration of the mechanism of disease occurrence and development and screening of treatment methods. Therefore, it is of great significance to establish an animal model of high-altitude cerebral edema that conforms to the characteristics of human diseases and has strong repeatability for research related to high-altitude cerebral edema.

[0003] The existing methods for establishing animal models of high-altitude cerebral edema mainly include two categories. One category is to treat animals for 3 to 7 days by simulating an environment at an altitude of 6,000 to 7,000 meters to induce the disease [CN202410780847.X A method for constructing an animal model of high-altitude cerebral edema]; the other category is to treat animals for 1 to 6 days by simulating an environment at an altitude of 5,000 to 6,000 meters, combined with exercise training [CN201310423304.4 A method for constructing an animal model of high-altitude cerebral edema], low temperature exposure or inflammatory drugs [Establishment and evaluation of a mouse model of brain damage caused by simulating high-altitude hypoxia inflammation] to induce the disease.

[0004] However, for humans, high altitude cerebral edema usually occurs within 1 to 3 days after rapidly entering an area above 4,000 meters above sea level. Studies have reported that the incidence of high altitude cerebral edema in people who rapidly enter an area above 4,300 meters above sea level within 2 days is 31%. However, existing methods are still unable to induce high altitude cerebral edema in animals within 1 day in an environment simulating an altitude of less than 5,000 meters. To this end, the present invention will solve this technical problem and provide a method for quickly establishing an animal model of high altitude cerebral edema within 1 day and in an environment simulating an altitude of 4,500 meters. Summary of the invention

[0005] In order to solve the problems existing in the prior art, the present invention proposes a method for quickly constructing an animal model of high altitude cerebral edema, comprising the following steps:

[0006] Step 1: The experimental animals were intraperitoneally injected with desmopressin acetate;

[0007] Step 2: Set the experimental chamber working parameters

[0008] The simulated altitude was set to 4500 meters, the modeling time was 24 hours, and the temperature during the modeling period was 24-26 degrees Celsius;

[0009] Step 3: The experimental animals in step 1 are placed in the experimental chamber and provided with drinking water for free access;

[0010] Step 4: Start the experimental chamber, and the experimental animals continue to model in the low-pressure environment of the experimental chamber for 24 hours;

[0011] Step 5: During the operation of the experimental chamber, the oxygen and carbon dioxide concentrations in the chamber are monitored in real time, the oxygen partial pressure is maintained at 11.6 kPa to 12.2 kPa, and the carbon dioxide volume ratio is maintained at no more than 0.5%;

[0012] Step 6: After the modeling is completed, the experimental chamber returns to normal pressure, the door is opened, the experimental animal is taken out, and the modeling is completed.

[0013] In some embodiments, the dosage of desmopressin acetate in step 1 is: 0.2% to 0.5% desmopressin acetate physiological saline solution by weight to volume, 50 ml to 80 ml per kg body weight.

[0014] In some embodiments, before modeling, the experimental chamber is adjusted to a set simulated altitude at an altitude ascent speed of not less than 5 m / s.

[0015] In some embodiments, at the end of modeling, the experimental chamber is restored to normal pressure at a rate of descent in altitude of not less than 5 m / s.

[0016] In some embodiments, after the experimental animals are modeled, the water content of the brain tissue is tested and the hippocampus tissue morphology is examined. The model is considered to be successfully constructed if the brain water content increases to more than 80% and the hippocampus neuronal degeneration and necrosis rate increases to more than 20%.

[0017] In some embodiments, the HACE animal model can be used for studies related to the pathogenesis, risk and prognosis markers, and therapeutic drug screening of HACE.

[0018] The present invention is the first to use a method of intraperitoneal injection of desmopressin acetate combined with a method of simulating 24 hours of exposure to an environment at an altitude of 4,500 meters to quickly complete the establishment of an animal model of high-altitude cerebral edema. Compared with the prior art, the present invention has at least the following two beneficial effects:

[0019] 1. The method provided by the present invention can realize the rapid establishment of an animal model of high-altitude cerebral edema, shorten the model construction time, and improve the model construction efficiency;

[0020] 2. The method provided by the present invention is more consistent with the altitude environment and induction duration that induce high altitude cerebral edema in humans. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0022] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0023] Figure 1 HE staining results of the hippocampus (100×, scale bar = 100 μm);

[0024] Figure 2 This is the result of Nissl body staining in the hippocampus (400×, scale bar = 50 μm);

[0025] Figure 3 is the rate of neuronal degeneration and necrosis in the hippocampus (**P<0.01);

[0026] Figure 4 is the weight of brain tissue (**P<0.01, ns P>0.05). DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0028] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in this application can be purchased from the market or prepared by existing methods.

[0029] Example 1

[0030] Twenty-four male ordinary grade 6-week-old Kunming mice, weighing 38 to 42 grams, were housed in a 12 / 12-hour circadian rhythm and a constant temperature of 25 degrees Celsius, with free access to food, and used in the experiment after 7 days of adaptation. The animals were randomly divided into two groups: a control group (CON) and a high-altitude cerebral edema model group (HACE), with 12 mice in each group.

[0031] The HACE group was processed as follows:

[0032] (1) Intraperitoneal injection of desmopressin acetate, the injection dose is 0.4% desmopressin acetate saline solution, 50 ml per kilogram of body weight;

[0033] (2) The working parameters of the hypobaric and hypoxic experimental chamber (DYC-3000, Fenglei, Guizhou, China) were set as follows: simulated altitude of 4500 m, altitude ascent or descent speed of 5 m / s, modeling time of 24 h, and temperature of 25 °C during modeling;

[0034] (3) The animals were placed in an experimental chamber and provided with free access to water;

[0035] (4) Start the experimental chamber, and the experimental animals will continue to model in the low-pressure environment of the experimental chamber for 24 hours;

[0036] (5) During the operation of the experimental chamber, the oxygen and carbon dioxide concentrations in the chamber shall be monitored in real time, the oxygen partial pressure shall be maintained at 11.6 kPa to 12.2 kPa, and the carbon dioxide volume ratio shall be maintained at no more than 0.5%;

[0037] (6) After the modeling is completed, the experimental chamber returns to normal pressure, the cabin door is opened, the experimental animal is taken out, and the modeling is completed.

[0038] For the experimental chamber set by air pressure, an altitude of 4500 meters is equivalent to an atmospheric pressure of 57 kPa to 59 kPa, so the atmospheric pressure can be set to 57 kPa to 59 kPa to simulate an altitude of 4500 meters. An altitude rise or fall speed of not less than 5 meters per second is equivalent to an atmospheric pressure drop or rise speed of not less than 0.048 kPa per second.

[0039] Animals in the CON group were treated as follows:

[0040] (1) Intraperitoneal injection of normal saline, the injection dose is 50 ml per kilogram of body weight;

[0041] (2) The mice were kept in a constant temperature environment of 25°C for 24 hours and were allowed to eat freely.

[0042] After the two groups of animals completed the above treatments, they were immediately killed by cervical dislocation and their brain tissues were obtained.

[0043] The brain tissues of 6 animals in each group were fixed with neutral formalin fixative (BL388A, Biosharp, China) for 24 hours, and then routinely embedded in paraffin and sectioned. Subsequently, hematoxylin-eosin (HE) staining solution (BL700A, Biosharp, China) was used for HE staining, and toluidine blue staining solution (BL999A, Biosharp, China) was used for Nissl body staining. The staining steps were carried out according to the instructions of the reagents. The morphological changes of brain tissue were observed under a microscope (BX43, Olympus, Japan).

[0044] The brain tissues of the remaining 6 animals in each group were dehydrated with absorbent paper and weighed (FA2003S, Qunan Instrument, China) to record the wet weight of the brain tissues; then they were placed in a constant temperature oven at 80 degrees Celsius (DHG-9070, Shanghai Yiheng, China) for drying for 48 hours, and the dry weight of the brain tissues was recorded.

[0045] The specific steps for evaluating the above test results are as follows:

[0046] (1) Based on the results of HE staining, the neurons in the hippocampus were counted and the neuronal degeneration and necrosis rate was calculated. The calculation formula was: neuronal degeneration and necrosis rate (%) = (number of degenerated and necrotic neurons (numbers) ÷ total number of neurons (numbers)) × 100%.

[0047] (2) Calculate the water content of brain tissue and the percentage of water content in brain tissue. The calculation formula is: brain tissue water content (g) = brain tissue wet weight (g) - brain tissue dry weight (g), brain tissue water content percentage (%) = (brain tissue water content (g) ÷ brain tissue wet weight (g)) × 100%.

[0048] (3) Data were expressed as median (minimum, maximum) and SPSS software (IBM, USA) was used to perform Mann-Whitney U test to compare the neuronal degeneration and necrosis rate in the hippocampus region, as well as the wet weight, dry weight, water content, and water content percentage of brain tissue between the two groups. P < 0.05 was considered statistically significant.

[0049] (4) The model was successfully constructed when the HACE group simultaneously met the conditions that the brain water content increased to more than 80% and the neuronal degeneration and necrosis rate in the hippocampus increased to more than 20%.

[0050] The test results are as follows:

[0051] (1) HE staining results show ( Figure 1 ), there was no significant change in the morphological structure of the hippocampus in the CON group, while in the HACE group, the hippocampus was loose and diffusely edematous, with some cell gaps enlarged, blood vessels dilated, and some neurons condensed or marginally degenerated and necrotic.

[0052] (2) Nissl body staining results show ( Figure 2 ), the Nissl bodies of the hippocampal neurons in the CON group were dark blue, while the Nissl bodies of the hippocampal neurons in the HACE group were reduced or even disappeared, which was consistent with the characteristics of neuronal damage.

[0053] (3) The results of hippocampal neuron counting showed that ( Figure 3 ), the degeneration and necrosis rate of the CON group was 5.75% (3.39%, 8.41%), and the degeneration and necrosis rate of the HACE group was 44.73% (20.24%, 58.47%); the statistical analysis results showed that the degeneration and necrosis rate of the hippocampus in the HACE group was significantly higher than that in the CON group (P=0.002).

[0054] (4) Brain tissue weighing and calculation results show ( Figure 4 ), the wet weight of brain tissue in CON group was 1.351 (1.304, 1.409) g, the dry weight was 0.311 (0.306, 0.328) g, the water content was 1.041 (0.998, 1.086) g, and the water content accounted for 76.9% (76.5%, 77.2%). The wet weight of brain tissue in HACE group was 1.769 (1.745, 1.843) g, the dry weight was 0.324 (0.318, 0.333) g, the water content was 1.446 (1.421, 1.510) g, and the water content accounted for 81.8% (81.3%, 82.1%). Statistical analysis results showed that the wet weight (P=0.002), water content (P=0.002) and water content ratio (P=0.002) of brain tissue in the HACE group were significantly higher than those in the CON group, but there was no significant difference in brain stem weight between the two groups (P=0.132).

[0055] The above results indicate that this example successfully and quickly constructed an animal model of high-altitude cerebral edema by intraperitoneally injecting desmopressin acetate into animals and simulating exposure to an environment at an altitude of 4,500 meters for 24 hours, which can increase the water content of the animal brain to more than 80% and the rate of neuronal degeneration and necrosis in the hippocampus to more than 20%. This model can well simulate the altitude environment and time background of high-altitude cerebral edema in humans, speed up the speed and efficiency of modeling, and has typical pathological characteristics of cerebral edema.

[0056] The test results show that this example successfully and quickly established an animal model of high-altitude cerebral edema by intraperitoneally injecting desmopressin acetate into animals and simulating exposure to an environment at an altitude of 4,500 meters for 24 hours. This model can well simulate the altitude environment and time background of high-altitude cerebral edema in humans, speed up the speed and efficiency of modeling, and has typical pathological characteristics of cerebral edema.

Claims

1. A method for rapidly constructing an animal model of high altitude cerebral edema, characterized in that: The following steps are involved: Step 1: The experimental animals were intraperitoneally injected with desmopressin acetate; Step 2: Set the experimental chamber working parameters The simulated altitude was set to 4500 meters, the modeling time was 24 hours, and the temperature during the modeling period was 24-26 degrees Celsius; Step 3: The experimental animals in step 1 are placed in the experimental chamber and provided with drinking water for free access; Step 4: Start the experimental chamber, and the experimental animals continue to model in the low-pressure environment of the experimental chamber for 24 hours; Step 5: During the operation of the experimental chamber, the oxygen and carbon dioxide concentrations in the chamber are monitored in real time, the oxygen partial pressure is maintained at 11.6 kPa to 12.2 kPa, and the carbon dioxide volume ratio is maintained at no more than 0.5%; Step 6: After the modeling is completed, the experimental chamber returns to normal pressure, the door is opened, the experimental animal is taken out, and the modeling is completed.

2. The construction method according to claim 1, characterized in that: The dosage of desmopressin acetate in step 1 is: 0.2% to 0.5% desmopressin acetate physiological saline solution by weight to volume, 50 ml to 80 ml per kg body weight.

3. The construction method according to claim 1, characterized in that: Before modeling, the experimental cabin was adjusted to the set simulated altitude at an altitude increase rate of not less than 5 m / s.

4. The construction method according to claim 3, characterized in that: At the end of modeling, the experimental chamber will be restored to normal pressure at a rate of descent in altitude of not less than 5 m / s.

5. The construction method according to claim 1, characterized in that: After the experimental animals were modeled, the water content of the brain tissue was tested and the hippocampus tissue morphology was examined. The model was considered to be successfully constructed if the brain water content increased to more than 80% and the hippocampus neuronal degeneration and necrosis rate increased to more than 20%.

6. The construction method according to claim 1, characterized in that: The high-altitude cerebral edema animal model can be used for related research on the pathogenesis, risk and prognosis markers, and therapeutic drug screening of high-altitude cerebral edema.